Ifenprodil currently in phase II development to be made available for compassionate use in serious cases of Coronivirus infection

The decision was made based on the results of an independent study of ifenprodil which showed a 40% improvement in mortality and significantly reduced acute lung injury in a H5N1 animal study. The drug is currently in phase 2 development for idiopathic fibrosis and chronic cough.

Biospace Inc.